Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT05986643

Brain Training to Improve Balance in Parkinson’s Disease

Brain Training to Improve Balance in Parkinson’s Disease — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT05986643.

📅 28 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT05986643
Sponsor
University of Leicester
Start
2023-08-04
ClinicaliQ Trial Snapshot
  • Brain Training to Improve Balance in Parkinson’s Disease — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT05986643.
  • Sponsor: University of Leicester.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

People living with Parkinson's (PwP) rank balance problems amongst the most disabling symptom. Over time, balance function continues to decline and PwP go on to fall, affecting between 45-68% of PwP. Falling directly impacts upon the individuals' quality of life (QoL), as it prevents patients from doing everyday activities, and places PwP at greater risk of other medical problems, such as fractures. New treatments are urgently needed to improve balance and reduce falls in order to improve QoL for PwP. The aim of this project is to achieve these goals…

Eligibility Snapshot
  • : People with Parkinson with mild-moderate disease and severe disability (but able to stand and walk unaided (Hoehn and Yahr stage ≤4) be eligible if: * in everyday life, they do less than the recommended aerobic exercise for older adults (i.e., vigorous exercise done

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Women’s voices to be at the heart of renewed health strategy
Cardiology / Cardiovascular · NHS England · 14 Apr 2026
Women's Health Strategy will be renewed with enhanced mechanisms to centre female patient voices in healthcare planning and delivery Strategy aims to…
View brief →
Clinical Brief
3D heart to let surgeons practise baby’s vital heart operation
Cardiology / Cardiovascular · BBC Health · 07 Apr 2026
3D heart models enable surgeons to practise complex congenital heart operations preoperatively, potentially improving surgical outcomes in neonatal cases Personalised anatomical models…
View brief →
Drug Science
RAAS Pathway
Cardiology / Cardiovascular · 04 Apr 2026
RAAS Pathway is a clinically relevant Drug Science explainer. The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade governing blood pressure, fluid balance,…
Explore mechanism →
Guideline
Stroke and TIA: Diagnosis and Initial Management (NICE NG128)
Cardiology / Cardiovascular · 27 Mar 2026
Use FAST recognition (Face, Arms, Speech, Time) in primary care to identify suspected stroke and arrange immediate hospital admission as a medical…
View guideline →
Guideline
Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
Cardiology / Cardiovascular · 25 Mar 2026
Percutaneous insertion of catheter-based left ventricular microaxial flow pumps may be considered for patients with acute cardiogenic shock refractory to medical therapy…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →